3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Brain Neoplasms
7
Breast Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
2
Oligodendroglioma
2
Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Astrocytoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Myelodysplastic Syndromes
1
Melanoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Surveys and Questionnaires
5
Pemetrexed
3
Paclitaxel
3
Gemcitabine
3
Docetaxel
3
Brachytherapy
3
pembrolizumab
2
Topotecan
2
Saline Solution
2
Radiotherapy
2
Radiation
2
FANG vaccine
2
Everolimus
2
Doxorubicin
2
Cisplatin
2
Carboplatin
2
CP protocol
2
temsirolimus
1
selinexor
1
osimertinib
1
niraparib
1
fosaprepitant
1
ferumoxtran-10
1
ferrous fumarate
1
durvalumab
1
cobimetinib
1
atezolizumab
1
alovudine
1
Vitamin D
1
Uterine Artery Embolization
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Uterine Neoplasms
×
alovudine
×
Clear all
NCT01399658
2023-03-14
AMIGO
Dana-Farber Cancer Institute
Phase 2
Completed
93 enrolled
5 charts